Skip to search formSkip to main contentSkip to account menu

MK 4827

Known as: MK-4827, MK4827 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

niraparib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum…
e16531 Background: Niraparib is an oral, potent PARP1/2 inhibitor that induces synthetic lethality in BRCA1/2 deficient and… 
2014
2014
The wide gulf between stage III and stage IV colon cancer.
2013
2013
Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer
Purpose: The therapeutic potential of PARP inhibitors is predicted to extend beyond BRCA mutant phenotypes to homologous… 
2013
2013
First in Human Trial of MK4827, a Poly(ADP)ribose Polymerase (PARP) Inhibitor With Antitumor Activity in BRCA Mutation Carrier and Sporadic Cancer Patients
2012
2012
352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
2012
2012
Therapeutics , Targets , and Chemical Biology Trapping of PARP 1 and PARP 2 by Clinical PARP Inhibitors
Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA… 
Review
2011
Review
2011
PARP inhibitors--current status and the walk towards early breast cancer.
2011
2011
PARP-1 inhibitor MK-4827 in combination with radiation as a treatment strategy for metastatic neuroblastoma.
9559 Background: Metastatic neuroblastoma continues to carry a dismal prognosis. Radiation is an important part of the treatment… 
2011
2011
Comparative PARP enzyme inhibition of PF-01367338, olaparib, and MK-4827.
e13552 Background: Within the past several years multiple PARP inhibitors have been entered into clinical trials, in a variety of… 
Review
2011
Review
2011
Abstract PL04-02: Synthetic lethality: Targeting DNA repair mechanisms in clinical trials
Epithelial carcinomas are in general diseases occurring as a result of the acquisition of and selection for multiple mutations in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)